CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE) - On February 16, 2017, Chief Executive Officer Jeff Jonas conducted an interview about SAGE-217 in major depressive disorder (MDD). During the course of the interview, Dr. Jonas acknowledged the industry’s interest in the MDD data. Dr. Jonas’ statements did not imply that the Company was in discussions with potential buyers. Sage remains focused on its core mission of developing novel medicines in CNS disorders. Sage will have no further comment on these matters and as a policy does not comment on speculation regarding M&A activities.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.